Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Appili Therapeutics Inc
(OP:
APLIF
)
0.0200
-0.0051 (-20.32%)
Streaming Delayed Price
Updated: 1:42 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,792
Open
0.0247
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0251
Today's Range
0.0200 - 0.0247
52wk Range
0.0135 - 0.0500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval
October 10, 2024
Via
Investor Brand Network
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
October 10, 2024
From
Aditxt, Inc.
Via
Business Wire
Performance
YTD
-22.48%
-22.48%
1 Month
-31.27%
-31.27%
3 Month
-8.68%
-8.68%
6 Month
-20.63%
-20.63%
1 Year
-35.28%
-35.28%
More News
Read More
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
October 08, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
October 08, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
October 03, 2024
Via
Investor Brand Network
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 03, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
September 24, 2024
Via
Investor Brand Network
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
August 29, 2024
From
Aditxt, Inc.
Via
Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
August 21, 2024
Via
Investor Brand Network
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
August 21, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
July 25, 2024
Via
Investor Brand Network
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 25, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
April 02, 2024
From
Aditxt, Inc.
Via
Business Wire
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
December 15, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
November 13, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
October 25, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
September 27, 2023
From
Appili Therapeutics
Via
Business Wire
Appili Therapeutics Presents at the 10th International Tularemia Conference
September 27, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
September 25, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
August 11, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics – Press Release Correction
June 23, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
June 23, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
May 24, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
April 03, 2023
From
Appili Therapeutics Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.